Federal health officials have signalled they're hunting ways to quickly learn if a third COVID-19 vaccine dose might better protect organ transplant recipients and other patients with weak immune systems.
While the vaccines are strongly effective in most people, many Americans with immune-suppressing health problems remain in limbo after immunisation, uncertain how protected they really are. France and Israel already have begun offering an extra dose to transplant recipients and other immunocompromised people. In the US, those patients increasingly are pushing for -- even lying to get -- another shot, too.
Thursday, advisers to the Centers for Disease Control and Prevention reviewed some small studies that hint, but don't prove, a third dose might help at least some immunocompromised patients. The panel can't formally recommend an extra dose without the Food and Drug Administration's permission, but several advisers asked if the government could allow worried patients to sign up for one as part of a study.
"We are actively looking into ways that could be done," replied CDC's Dr Amanda Cohn. "Stay tuned. We are working through those issues.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)